We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder

By LabMedica International staff writers
Posted on 07 Oct 2026

Retinitis pigmentosa is an inherited eye condition that causes progressive vision loss. More...

Genetic diagnosis can be difficult when a patient’s symptoms do not fit the expected pattern for a known disease gene, particularly when broader systemic features that usually guide diagnosis are absent. Researchers now describe an unexpected link between inherited blindness and a gene typically associated with a rare metabolic disorder.

Greenwood Genetic Center (Greenwood, SC, USA) led an international study identifying changes in the IDUA gene in individuals diagnosed with retinitis pigmentosa. The IDUA gene is typically associated with mucopolysaccharidosis type I, a rare metabolic condition. However, many individuals in the study did not have the severe physical disability, heart problems, or skeletal abnormalities typically associated with mucopolysaccharidosis type I, even at older ages.

The study examined 14 individuals from 12 families with retinitis pigmentosa. Genetic testing showed that all carried changes in both copies of the IDUA gene. Researchers used a functional platform developed at Greenwood Genetic Center to investigate how these IDUA changes affect the body’s ability to produce a critical enzyme.

Laboratory work found that some of the genetic changes allow a very small amount of enzyme activity to remain. Researchers indicated that this residual activity may help explain why these individuals developed retinal disease without the more widespread problems seen in mucopolysaccharidosis type I. 

The findings broaden the known range of conditions associated with IDUA and suggest that the gene should be considered when evaluating patients with inherited retinal disease who lack typical mucopolysaccharidosis type I features.

The study was published in The American Journal of Human Genetics on October 6, 2026. Collaborating institutions included Greenwood Genetic Center, University of Manchester, and more than 20 other centers involved in inherited retinal disease and metabolic disorders. The work also emphasizes the importance of understanding how genetic variants affect the body, rather than identifying variants alone.

“Genetic conditions do not always follow the patterns we expect. Our findings show that changes in the same gene can sometimes affect the retina while leaving other parts of the body largely unaffected. This phenomenon may represent a significant cause of blindness in patients who remain undiagnosed,” said Gavin Arno, Ph.D., associate director of research at Greenwood Genetic Center and the study’s corresponding author.

“This is an excellent example of why genetic diagnosis cannot always stop with identifying a variant in a gene. By combining genetic analysis with laboratory studies, like enzyme levels, we can better understand why a condition may look very different from one person to another,” said Richard Steet, Ph.D., director of research at Greenwood Genetic Center and a study author.

Related Links
Greenwood Genetic Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.